Wells Fargo & Company MN Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Wells Fargo & Company MN lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 53.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 104,163 shares of the biotechnology company's stock after buying an additional 36,166 shares during the quarter. Wells Fargo & Company MN owned approximately 0.05% of BioCryst Pharmaceuticals worth $783,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of BCRX. SkyView Investment Advisors LLC raised its holdings in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company's stock worth $99,000 after buying an additional 3,000 shares during the period. Franklin Resources Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 177.8% in the third quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company's stock worth $1,968,000 after buying an additional 168,790 shares during the period. Exome Asset Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the third quarter worth approximately $1,493,000. Principal Financial Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock worth $3,127,000 after buying an additional 375,890 shares during the period. Finally, KBC Group NV raised its holdings in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after buying an additional 4,537 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 4.9 %

Shares of NASDAQ BCRX opened at $8.85 on Thursday. The stock has a market capitalization of $1.85 billion, a PE ratio of -14.51 and a beta of 1.75. The stock's fifty day simple moving average is $7.67 and its two-hundred day simple moving average is $7.78. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.15 and a 12-month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The company's quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.28 earnings per share. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research reports. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday. They set an "overweight" rating and a $20.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Royal Bank of Canada restated an "outperform" rating and set a $11.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. Wedbush initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective on the stock. Finally, JMP Securities restated a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $16.13.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.